New RA StudyThe study is funded by the American College of Rheumatology: Rheumatology Research Foundation. The study is a Randomized trial that will administer a single dose of Zostavax® vs Placebo (1:1) to patients who are eligible to enroll. Zostavax® is a live attenuated vaccine developed by Merck and approved for use in the general population of persons aged 50 years or older, regardless of previous Herpes Zoster (HZ) or varicella history. Patients with RA or other inflammatory arthritis conditions are at a higher risk of HZ compared to the general population. Due to this risk, preventing it is a major concern and it is of key importance to evaluate the safety and effectiveness of Zostavax® in RA and other inflammatory arthritis patients using anti-TNF therapy.
To be eligible to enroll, patients must have a diagnosis of RA or another inflammatory arthritis, be at least 50 years old, test positive for the Varicilla Zoster Antibodies, and currently using an anti-TNF therapy at the time of vaccination. Patients who meet the criteria to enroll in the study will receive the Zostavax® vs Placebo injection and monitored for 6 weeks following administration and return for a 6 week follow-up visit.
Anita Turner, RN Study Coordinator email@example.com 205-934-2993
WelcomeWelcome to the Arthritis Clinical Intervention Program (ACIP) at UAB.
ACIP is a full service clinical trial unit that conducts studies in rheumatology (Phase I - IV).
Currently, we are recruiting for studies in: rheumatoid arthritis (RA), gout, scleroderma, lupus and vasculitis.
Please contact us for more information.